The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
Open accessAbstract
OBJECTIVE: To identify biomarker patterns typical for Alzheimer disease (AD) in an independent, unsupervised way, without using information on the clinical diagnosis. DESIGN: Mixture modeling approach. SETTING: Alzheimer's Disease Neuroimaging Initiative database. PATIENTS OR OTHER PARTICIPANTS: Cognitively normal persons, patients with AD, and individuals with mild cognitive impairment. MAIN OUTCOME MEASURES: Cerebrospinal fluid-derived beta-amyloid protein 1-42, total tau protein, and phosphorylated tau(181P) protein concentrations were used as biomarkers on a clinically well-characterized data set. The outcome of the qualification analysis was validated on 2 additional data sets, 1 of which was autopsy confirmed. RESULTS: Using the US Alzheimer's Disease Neuroimaging Initiative data set, a cerebrospinal fluid beta-amyloid protein 1-42/phosphorylated tau(181P) biomarker mixture model identified 1 feature linked to AD, while the other matched the "healthy" status. The AD signature was found in 90%, 72%, and 36% of patients in the AD, mild cognitive impairment, and cognitively normal groups, respectively. The cognitively normal group with the AD signature was enriched in apolipoprotein E epsilon4 allele carriers. Results were validated on 2 other data sets. In 1 study consisting of 68 autopsy-confirmed AD cases, 64 of 68 patients (94% sensitivity) were correctly classified with the AD feature. In another data set with patients (n = 57) with mild cognitive impairment followed up for 5 years, the model showed a sensitivity of 100% in patients progressing to AD. CONCLUSIONS: The mixture modeling approach, totally independent of clinical AD diagnosis, correctly classified patients with AD. The unexpected presence of the AD signature in more than one-third of cognitively normal subjects suggests that AD pathology is active and detectable earlier than has heretofore been envisioned.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abnormal CSF Aβ42 values were defined using the previously established cut-off of <192 ng/L57–59.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Elements of Statistical Learning
Hastie, T., Friedman, J., & Tibshirani, R. (2001) · Springer Series in Statistics · doi:10.1007/978-0-387-21606-5 · Cited by 24,162
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
ROCR: visualizing classifier performance in R
Sing, T., Sander, O., Beerenwinkel, N., & Lengauer, T. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti623 · Cited by 3,172
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2006) · Brain · doi:10.1093/brain/awl178 · Cited by 614
Cited by
Sorted by citations
Items 101–200 of 455
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Kang, J., Korecka, M., Figurski, M., Toledo, J. B., Blennow, K., Zetterberg, H., Waligórska, T., Brylska, M., Fields, L., Shah, N., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.003 · Cited by 100
Vos, S. J. B., Gordon, B. A., Su, Y., Visser, P. J., Holtzman, D. M., Morris, J. C., Fagan, A. M., & Benzinger, T. L. S. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.025 · Cited by 98
Assessment of cognition in early dementia
Silverberg, N. B., Ryan, L. M., Carrillo, M. C., Sperling, R. A., Petersen, R. C., Posner, H. B., Snyder, P. J., Hilsabeck, R. C., Gallagher, M., Raber, J., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.001 · Cited by 109
Estrogen Regulation of Mitochondrial Bioenergetics
Yao, J., & Brinton, R. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00010-6 · Cited by 103
Irwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96
Ewers, M., Insel, P. A., Jagust, W. J., Shaw, L. M. J., Trojanowski, J. Q., Aisen, P. S. S., Petersen, R. C., Schuff, N. W., Weiner, M. W., & Initiative, A. D. N. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr271 · Cited by 104
Javed, A. R., Saadia, A., Mughal, H., Gadekallu, T. R., Rizwan, M., Maddikunta, P. K. R., Mahmud, M., Liyanage, M., & Hussain, A. (2023) · Cognitive Computation · doi:10.1007/s12559-023-10153-4 · Cited by 99
Bendlin, B. B., Carlsson, C. M., Johnson, S. C., Zetterberg, H., Blennow, K., Willette, A. A., Okonkwo, O. C., Sodhi, A., Ries, M. L., Birdsill, A. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037720 · Cited by 91
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Bertens, D., Tijms, B. M., Scheltens, P., Teunissen, C. E., & Visser, P. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0233-7 · Cited by 91
Quantitative structural MRI for early detection of Alzheimer's disease
McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90
Toledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
Biomarkers in the diagnosis and management of Alzheimer’s disease
Wurtman, R. J. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.034 · Cited by 89
Larrosa, J. M., García‐Martín, E., BAMBO, M., Pinilla, J., Polo, V., Otín, S., Satué, M., Herrero, R., & Pablo, L. E. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13629 · Cited by 91
Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative
Weiner, M. W., & Veitch, D. P. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.007 · Cited by 85
Soldan, A., Pettigrew, C. A., Li, S., Wang, M., Moghekar, A., Selnes, O. A., Albert, M., & O’Brien, R. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.017 · Cited by 89
Sierks, M. R., Chatterjee, G., McGraw, C. E., Kasturirangan, S., Schulz, P., & Prasad, S. (2011) · Integrative Biology · doi:10.1039/c1ib00018g · Cited by 84
de Vries, L. E., Huitinga, I., Kessels, H. W. H. G., Swaab, D. F., & Verhaagen, J. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00719-7 · Cited by 85
Development and validation of language and visuospatial composite scores in ADNI
Choi, S., Mukherjee, S., Gibbons, L. E., Sanders, R. E., Jones, R. N., Tommet, D., Mez, J., Trittschuh, E. H., Saykin, A. J., Lamar, M., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12072 · Cited by 83
Samtani, M. N., Farnum, M. A., Lobanov, V. S., Yang, E., Raghavan, N., DiBernardo, A., Narayan, V. A., & Initiative, A. T. A. D. N. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011405497 · Cited by 81
Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease
Shaw, L. M. J., Waligórska, T., Fields, L., Korecka, M., Figurski, M., Trojanowski, J. Q., Eichenlaub, U., Wahl, S., Quan, M., Pontecorvo, M. J., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.002 · Cited by 81
Siegler, I. C., Elias, M. F., Brummett, B. H., & Bosworth, H. B. (2012) · Wiley eBooks · doi:10.1002/9781118133880.hop209020 · Cited by 81
Norambuena, A., Wallrabe, H., McMahon, L., Silva, A., Swanson, E., Khan, S. S., Baerthlein, D., Kodis, E., Oddo, S., Mandell, J. W., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.015 · Cited by 79
Prevention trials in Alzheimer's disease: An EU-US task force report
Vellas, B. J., Aisen, P. S. S., Sampaio, C., Carrillo, M. C., Scheltens, P., Scherrer, B., Frisoni, G. B., Weiner, M. W., Schneider, L. S. S., Gauthier, S. G., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.014 · Cited by 78
Weiner, M. W., Veitch, D. P., Hayes, J., Neylan, T. C., Grafman, J. H., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.005 · Cited by 81
Tarnanas, I., Tsolaki, M., Nef, T., M. Müri, R., & Mosimann, U. P. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.002 · Cited by 77
González‐Martínez, Á., Rosado, B., Pesini, P., Suarez, M. L., Santamarina, G., García‐Belenguer, S., Villegas, A., Monleón, I., & Sarasa, M. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2011.02.013 · Cited by 85
2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease
Fargo, K. N., Aisen, P. S. S., Albert, M., Au, R., Corrada, M. M., DeKosky, S. T., Drachman, D. A., Fillit, H. M., Gitlin, L. N., Haas, M., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.08.103 · Cited by 77
Multiple opioid receptor systems in brain and spinal cord: Part 2.
Yaksh, T. L. (1984) · PubMed · Cited by 76
de la Escosura‐Muñiz, A., Plichta, Z., Horák, D., & Merkoçi, A. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.07.086 · Cited by 75
Li, Q., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A. R., Laughton, K. M., Pertile, K. K., Fowler, C. J., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150247 · Cited by 75
Peripheral Blood Mononuclear Cells as a Laboratory to Study Dementia in the Elderly
Arosio, B., D’Addario, C., Gussago, C., Casati, M., Tedone, E., Ferri, E., Nicolini, P., Rossi, P. D., Maccarrone, M., & Mari, D. (2014) · BioMed Research International · doi:10.1155/2014/169203 · Cited by 73
A generic operational strategy to qualify translational safety biomarkers
Matheis, K. A., Laurie, D., Andriamandroso, C., Arber, N., Badimón, L., Benain, X., Bendjama, K., Clavier, I., Colman, P., Firat, H., et al. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.04.011 · Cited by 73
Mollenhauer, B., Parnetti, L., Rektorová, I., Kramberger, M. G., Pikkarainen, M., Schulz‐Schaeffer, W., Aarsland, D., Svenningsson, P., Farotti, L., Verbeek, M. M., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13390 · Cited by 73
Britschgi, M., Rufibach, K., Huang, S. L. B., Clark, C. M., Kaye, J. A., Li, G., Peskind, E. R., Quinn, J. F., Galasko, D. R., & Wyss‐Coray, T. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.008862 · Cited by 73
(ADNI), T. A. D. N. I., Bouallègue, F. B., Mariano‐Goulart, D., & Payoux, P. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0260-z · Cited by 73
Leuzy, A., Ashton, N. J., Mattsson, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Nordberg, A. K., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 73
Lacsogram: A New EEG Tool to Diagnose Alzheimer's Disease
Rodrigues, P. M., Bispo, B. C., Garrett, C., Alves, D., Teixeira, J. P., & Freitas, D. (2021) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2021.3069789 · Cited by 69
Schmand, B. A., Eikelenboom, P., van Gool, W. A., & Initiative, T. A. D. N. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03539.x · Cited by 72
Wu, G., Sankaranarayanan, S., Wong, J., Tugusheva, K., Michener, M. S., Shi, X., Cook, J. J., Simon, A. J., & Savage, M. J. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23122 · Cited by 68
Cognitive decline in the elderly: Is anaesthesia implicated?
SILBERT, B. S., Evered, L. A., & Scott, D. A. (2011) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2011.05.001 · Cited by 68
CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease
Rosenmann, H. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9665-5 · Cited by 72
Kile, S. J., Au, W. J., Parise, C. A., Rose, K., Donnel, T., Hankins, A. I., Chan, M., & Ghassemi, A. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311486 · Cited by 68
The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease
Iulita, M. F., & Cuello, A. C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921100030 · Cited by 69
Quantifying the Pathophysiological Timeline of Alzheimer's Disease
Yang, E., Farnum, M. A., Lobanov, V. S., Schultz, T., Raghavan, N., Samtani, M. N., Novak, G., Narayan, V. A., DiBernardo, A., & Initiative1, A. T. A. D. N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110551 · Cited by 66
Early detection of neurodegenerative diseases
Sheinerman, K. S., & Umansky, S. R. (2012) · Cell Cycle · doi:10.4161/cc.23067 · Cited by 66
Hyperphosphorylation Results in Tau Dysfunction in DNA Folding and Protection
Lü, Y., He, H.-J., Zhou, J., Jun-Ye, M. I. A. O., Lü, J., He, Y.-G., Pan, R., Yan, W., Liu, Y. M., & He, R. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130602 · Cited by 65
Hanzel, C. E., Iulita, M. F., Eyjolfsdottir, H., Hjorth, E., Schultzberg, M., Eriksdotter, M., & Cuello, A. C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132282 · Cited by 66
Nettiksimmons, J., Harvey, D. J., Brewer, J. B., Carmichael, O. T., DeCarli, C. S., Jack, C. R., Petersen, R. C., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.025 · Cited by 64
Bartlett, J. W., Frost, C. D., Mattsson, N., Skillbäck, T. B., Blennow, K., Zetterberg, H., & Schott, J. M. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.49 · Cited by 63
Alkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 68
Mohajeri, M., Behnam, B., Barreto, G. E., & Sahebkar, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.023 · Cited by 61
Shigemizu, D., Akiyama, S., Asanomi, Y., Boroevich, K. A., Sharma, A. K., Tsunoda, T., Matsukuma, K., Ichikawa, M., Sudo, H., Takizawa, S., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0324-7 · Cited by 61
Mayeux, R. P., Reitz, C., Brickman, A. M., Haan, M. N., Manly, J. J., Glymour, M. M., Weiss, C. C., Yaffe, K. S., Middleton, L. E., Hendrie, H. C., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.11.005 · Cited by 63
Cerebrospinal fluid ratios with Aβ 42 predict preclinical brain β‐amyloid accumulation
Racine, A. M., Koscik, R. L., Nicholas, C. R. N., Clark, L. R., Okonkwo, O. C., Oh, J. M., Hillmer, A. T., Murali, D., Barnhart, T. E., Betthauser, T. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.006 · Cited by 58
Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology
Negash, S., Xie, S. X., Davatzikos, C. A., Clark, C. M., Trojanowski, J. Q., Shaw, L. M. J., Wolk, D. A., & Arnold, S. E. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.009 · Cited by 57
Delor, I., Charoin, J.-E., Gieschke, R., Retout, S., Jacqmin, P., & Initiative, A. D. N. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.54 · Cited by 57
Bastard, N. L., Coart, E., Vanderstichele, H., Vanmechelen, E., Martin, J., & Engelborghs, S. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121246 · Cited by 55
Herskovits, A. Z., & Growdon, J. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.151 · Cited by 53
Samtani, M. N., Raghavan, N., Shi, Y., Novak, G., Farnum, M. A., Lobanov, V. S., Schultz, T., Yang, E., DiBernardo, A., Narayan, V. A., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04308.x · Cited by 52
Complex network analysis of MCI-AD EEG signals under cognitive and resting state
Das, S. S., & Puthankattil, S. D. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146743 · Cited by 52
Zolochevska, O., & Taglialatela, G. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160518142110 · Cited by 49
The plant sterol brassicasterol as additional CSF biomarker in Alzheimer’s disease
Vanmierlo, T., Popp, J., Kölsch, H., Friedrichs, S., Jessen, F., Stoffel‐Wagner, B., Bertsch, T., Hartmann, T., Maier, W., von Bergmann, K., et al. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01713.x · Cited by 49
Pontecorvo, M. J., & Mintun, M. A. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt70 · Cited by 49
Johnson, R. D., Schauerte, J. A., Wisser, K. C., Gafni, A., & Steel, D. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023970 · Cited by 48
Lathuilière, A., Mach, N., & Schneider, B. L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160510578 · Cited by 48
Cerebrospinal Fluid Aβ and Tau Level Fluctuation in an Older Clinical Cohort
Moghekar, A. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.732 · Cited by 46
Escudero, J., Zajicek, J., & Ifeachor, E. (2011) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2011.6091597 · Cited by 46
Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls
Mattsson, N., Insel, P. S., Donohue, M., Jagust, W., Sperling, R., Aisen, P., & Weiner, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4530 · Cited by 45
Tau is reduced in AD plasma and validation of employed ELISA methods.
Sparks, D. L., Kryscio, R. J., Sabbagh, M. N., Ziolkowski, C. H. J., Lin, Y., Sparks, L. M., Liebsack, C., & Johnson‐Traver, S. (2012) · Europe PMC (PubMed Central) · Cited by 45
Flood, D. G., Marek, G. J., & Williams, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.021 · Cited by 46
Kok, F. K., van Leerdam, S., & de Lange, E. C. M. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-210607 · Cited by 46
Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials
Andrews, K. A., Marc Modat, A., Macdonald, K. E., Yeatman, T., Cardoso, M. J., Leung, K. K., Barnes, J., Villemagne, V. L., Rowe, C. C., Fox, N. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058816 · Cited by 48
Schneider, L. S. S., Kennedy, R., Cutter, G., & Initiative, A. D. N. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.07.004 · Cited by 44
Nakajima, M., Miyajima, M., Ogino, I., Akiba, C., Kawamura, K., Kamohara, C., Fusegi, K., Harada, Y., Hara, T., Sugano, H., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180557 · Cited by 43
Sala, A., Nordberg, A. K., Rodriguez‐Vieitez, E., & Initiative, A. D. N. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00950-w · Cited by 43
Martínez-Dubarbie, F., Guerra-Ruiz, A., López-García, S., Lage, C., Fernández-Matarrubia, M., Infante, J., Pozueta-Cantudo, A., García-Martínez, M., Corrales-Pardo, A., Bravo, M., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01319-1 · Cited by 47
An MRI-Derived Definition of MCI-to-AD Conversion for Long-Term, Automatic Prognosis of MCI Patients
Aksu, Y., Miller, D. J., Kesidis, G., Bigler, D. C., & Yang, Q. X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025074 · Cited by 42
Gray matter structural covariance networks changes along the Alzheimer's disease continuum
Li, K., Luo, X., Zeng, Q., Huang, P., Shen, Z., Xu, X., Xu, J., Wang, C., Zhou, J., & Zhang, M. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101828 · Cited by 42
MMSE Subscale Scores as Useful Predictors of AD Conversion in Mild Cognitive Impairment
Choe, Y. M., Lee, B. C., Choi, I.-G., Suh, G., Lee, D. Y., & Kim, J. W. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s263702 · Cited by 42
Biomarkers for early detection of Alzheimer disease.
Barber, R. C. (2010) · PubMed · Cited by 41
Biomarkers for Predicting Cognitive Decline in those with Normal Cognition
Steenland, K., Initiative, A. D. N., Zhao, L., Goldstein, F. C., Cellar, J. S., & Lah, J. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-2014-131343 · Cited by 44
The legacy of nanotechnology: Revolution and prospects in neurosurgery
Khawaja, A. M. (2011) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.10.002 · Cited by 42
Kim, J. W., Byun, M. S., Sohn, B. K., Yi, D., Seo, E. H., Choe, Y. M., Kim, S. G., Choi, H. J., Lee, J. H., Chee, I., et al. (2017) · Psychiatry Investigation · doi:10.4306/pi.2017.14.4.420 · Cited by 42
Schmand, B. A., Initiative, A. D. N., Eikelenboom, P., & van Gool, W. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111703 · Cited by 41
Luo, X., Li, K., Zeng, Q., Huang, P., Jiaerken, Y., Wang, S., Shen, Z., Xu, X., Xu, J., Wang, C., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00904 · Cited by 40
Yu, P., Initiative, A. D. N., Dean, R. A., Hall, S. D., Qi, Y., Sethuraman, G., Willis, B. A., Siemers, E., Martényi, F., Tauscher, J. T., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120832 · Cited by 42
McMillan, C. T., & Wolk, D. A. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312690 · Cited by 39
Longitudinal Alteration of Intrinsic Brain Activity in the Striatum in Mild Cognitive Impairment
Ren, P., Initiative, T. A. D. N., Lo, R. Y., Chapman, B. P., Mapstone, M. E., Porsteinsson, A. P., & Lin, F. V. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160368 · Cited by 39
Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years
Josephs, K. A., Weigand, S. D., & Whitwell, J. L. (2022) · Neurology · doi:10.1212/wnl.0000000000200287 · Cited by 39
Variation in Variables that Predict Progression from MCI to AD Dementia over Duration of Follow-up
Li, S., Okonkwo, O. C., Albert, M., & Wang, M. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.7726/ajad.2013.1002 · Cited by 39
Role of FABP3 as Biomarker in Alzheimer's Disease and Synucleinopathies
Sepe, F. N., Chiasserini, D., & Parnetti, L. (2018) · Future Neurology · doi:10.2217/fnl-2018-0003 · Cited by 38
Early Prediction of Alzheimer’s Disease Using Null Longitudinal Model-Based Classifiers
Gavidia‐Bovadilla, G., Kanaan-Izquierdo, S., Mataró, M., Perera-Lluna, A., & Initiative, A. D. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0168011 · Cited by 37
Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010
Khachaturian, Z. S., Petersen, R. C., Snyder, P. J., Khachaturian, A. S., Aisen, P. S. S., de Leon, M. J., Greenberg, B., Kukull, W. A., Maruff, P. T., Sperling, R. A., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.02.005 · Cited by 36
Evaluation of suspected dementia.
Simmons, B. B., Hartmann, B., & DeJoseph, D. (2011) · PubMed · Cited by 36
Supramolecular Non-Amyloid Intermediates in the Early Stages of α-Synuclein Aggregation
Fauerbach, J. A., Yushchenko, D. A., Shahmoradian, S. H., Chiu, W., Jovin, T. M., & Jares-Erijman, E. A. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.01.051 · Cited by 35
Galindo, A. N., Kussmann, M., & Dayon, L. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b02748 · Cited by 35
Translational paradigms in pharmacology and drug discovery
Mullane, K., Winquist, R. J., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.019 · Cited by 34
A Network-Based Perspective in Alzheimer's Disease: Current State and an Integrative Framework
Dragomir, A., Vrahatis, A. G., & Bezerianos, A. (2018) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2018.2863202 · Cited by 34
Using Biomarkers to Improve Detection of Alzheimer’s Disease
Biagioni, M. C., & Galvin, J. E. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.11 · Cited by 35
Beta-Amyloid Monomer and Insulin/IGF-1 Signaling in Alzheimer's Disease
Giuffrida, M. L., Tomasello, M. F., Caraci, F., Chiechio, S., Nicoletti, F., & Copani, A. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8313-6 · Cited by 35
Metadata
- Authors
- De Meyer, G.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2010-08-01
- Volume
- 67
- Issue
- 8
- Pages
- 949
- ISSN
- 0003-9942 (ISSN-L)
- PMC
- PMC2963067
- OpenAlex
- W2141854336
- Cited by
- 462
- References
- 24
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 14 · 2023: 8 · 2022: 13 · 2021: 18 · 2020: 43 · 2019: 16 · 2018: 19 · 2017: 24 · 2016: 15 · 2015: 31 · 2014: 44 · 2013: 35 · 2012: 58
- FWCI
- 42.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, P30AG010124, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, biomarker signatures, cerebrospinal fluid, amyloid-beta 42, phosphorylated tau, total tau, mixture models, cognitively normal elderly, mild cognitive impairment, APOE ε4, unsupervised classification
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Female, Follow-Up Studies, Humans, Male, Peptide Fragments, ROC Curve, Reproducibility of Results, Biomarkers, Geriatric Assessment, Amyloid beta-Peptides, tau Proteins, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
